Visão geral da empresa OrthoLogic
Biotecnologia e farmacêuticaIndústria
OrthoLogic, doing business as Capstone Therapeutics, is trying to make sense of scarred skin and damaged hearts with its biopharmaceutical products designed to repair the body's tissues. The biotechnology company is focused on a couple of synthetic peptide technologies that may accelerate healing. Its Chrysalin program has yielded several potential therapies, including TP508, which the company is evaluating as a treatment for vascular diseases, as well as diabetic foot ulcers. OrthoLogic acquired another candidate, AZX100, in 2006 and has begun clinical testing on the drug as a treatment for dermal scarring.
